Hematologic Oncology | Specialty

Dr. Deol on the Safety of CAR T-Cell Therapy

September 28th 2018

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Dr. Radich on Treatment Discontinuation in CML Off Trial

September 28th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

Expert Shares Insight on Impact of Bone Marrow Transplant on MDS Paradigm

September 27th 2018

Joseph Uberti, MD, PhD, discusses the risk and benefit of a bone marrow transplant for patients with myelodysplastic syndrome.

Future AML Advancements Include Next-Generation Targeted Therapies

September 27th 2018

Jay Yang, MD, explains that drug development is not as simple as identifying a molecular target and matching inhibitor.

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

September 26th 2018

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Dr. Yang on the Future of Acute Myeloid Leukemia

September 26th 2018

Jay Yang, MD, oncologist, Barbara Ann Karmanos Cancer Institute, discusses the future of acute myeloid leukemia (AML).

Expert Recaps Advances in AML

September 26th 2018

Rami S. Komrokji, MD, reflects on the diverse acute myeloid leukemia treatment landscape and touches on the prognostic importance of biomarkers.

Dr. Zonder on Induction Therapy in Newly Diagnosed Multiple Myeloma

September 26th 2018

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Uberti on Transplant in Myelodysplastic Syndrome

September 26th 2018

Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).

Dr. Kreitman on the Prognosis of Hairy Cell Leukemia

September 25th 2018

Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the prognosis for patients diagnosed with hairy cell leukemia.

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

FDA Lifts Partial Clinical Hold on Tazemetostat Trials

September 24th 2018

The FDA has lifted a partial clinical hold on tazemetostat trials, reopening enrollment to clinical studies examining the EZH2 inhibitor in patients with various solid tumors and hematologic malignancies.

Recent Data Support TKI Discontinuation in Patients With CML

September 24th 2018

Kendra Sweet, MD, sheds light on data regarding treatment discontinuation and how they impact patients with chronic myeloid leukemia.

Dr. Cohen on the Evolution of Antibodies in Lymphoma

September 22nd 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.

Future Treatment Approaches to AML

September 20th 2018

Moving the AML Treatment Landscape Forward

September 20th 2018

Optimizing the Use of FLT3 Inhibitor Therapy for AML

September 20th 2018

Long-Term Challenges With FLT3 Inhibition in AML

September 20th 2018

Testing for FLT3 Mutations in the Community Setting of AML

September 20th 2018

Quizartinib's Potential Role in Treating AML

September 20th 2018